Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, United Kingdom.
Neuropharmacology. 2013 Oct;73:10-8. doi: 10.1016/j.neuropharm.2013.05.019. Epub 2013 May 24.
Acetylcholinesterase (AChE) is now well known to have a secondary, non-enzymatic function independent of cholinergic transmission. In the last decade, the part of the molecule responsible for this action has been identified, i.e. a 14 amino acid peptide fragment ('T14'), deriving from the C-terminus of AChE: this peptide has been shown to be bioactive in a range of preparations and to act at an allosteric site on α₇ nicotinic acetylcholine receptors (α₇-nAChRs). Of particular significance is the finding that AChE-related peptides trigger calcium-induced neurotoxicity that may be pivotal in the process of neurodegenerative diseases, such as Alzheimer's. However to date all studies have been performed on isolated cell preparations. The aim of this study was therefore to characterise the bioactivity of T14 on meso-scale in vitro cortical networks ('neuronal assemblies') from rat brain slices containing orbitofrontal cortex. Local field potential (LFP) recordings showed that the T14 peptide has a selective, holistic action on cortical networks in a modulatory biphasic manner i.e. predisposing excitation at concentrations of up to 1 μM, after which the trend is reversed in favour of inhibition at higher doses (>1 μM). By contrast, a scrambled variant of the T14 peptide sequence (S14), showed no significant changes in neuronal activation. Optical imaging using voltage-sensitive dyes (VSDI) corroborated the electrophysiological findings and also provided further insight into the spatial dynamics of the effects of the peptide: T14 application had a facilitatory effect i.e. increased the time-course of activation at sub-micromolar concentrations only (700 nM) without significantly affecting the spread of evoked assemblies. Moreover: co-applying T14 with the α₇-nAChR competitive antagonist methyllycaconitine (MLA) produced inhibition in activation synchrony not seen with either agent on their own, suggesting an additive inhibitory effect. In conclusion, the T14 peptide derived from AChE produced a dose-dependent biphasic modulation of cortical networks activity dependent on the α₇-nAChR: these findings should thus provide a more comprehensive insight into the immediate actions of a novel bioactive agent of high potential relevance to neurodegenerative disorders such as Alzheimer's disease.
乙酰胆碱酯酶(AChE)现在被广泛认为具有非酶的辅助功能,与胆碱能传递无关。在过去的十年中,负责这种作用的分子部分已经被确定,即来自 AChE C 末端的 14 个氨基酸肽片段(“T14”):该肽已被证明在多种制剂中具有生物活性,并在α₇烟碱型乙酰胆碱受体(α₇-nAChRs)的变构部位起作用。特别重要的是发现 AChE 相关肽引发钙诱导的神经毒性,这可能在神经退行性疾病(如阿尔茨海默病)的过程中起关键作用。然而,迄今为止所有研究都是在分离的细胞制剂上进行的。因此,本研究的目的是在含有眶额皮层的大鼠脑片的中尺度体外皮质网络(“神经元组装”)上对 T14 的生物活性进行特征描述。局部场电位(LFP)记录显示,T14 肽以调节性双相方式对皮质网络具有选择性、整体作用,即在高达 1 μM 的浓度下促进兴奋,之后在更高剂量(>1 μM)下,趋势有利于抑制。相比之下,T14 肽序列的乱序变体(S14)对神经元激活没有显著变化。使用电压敏感染料(VSDI)的光学成像证实了电生理发现,并进一步深入了解了肽的空间动力学:T14 应用具有促进作用,即在亚微米摩尔浓度(700 nM)下仅增加激活的时程,而不会显著影响诱发组装的扩散。此外:T14 与 α₇-nAChR 竞争性拮抗剂甲基六氢烟碱(MLA)共同应用会产生激活同步的抑制作用,而单独使用任何一种药物都不会产生这种作用,表明存在相加抑制作用。总之,源自 AChE 的 T14 肽对皮质网络活性产生剂量依赖性双相调节,依赖于 α₇-nAChR:这些发现应该为新型生物活性药物对阿尔茨海默病等神经退行性疾病的直接作用提供更全面的了解。